Cytek Biosciences Inc (CTKB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has a cash flow conversion efficiency ratio of -0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($327.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cytek Biosciences Inc (CTKB) net asset quality to measure how much of total assets are equity-financed.
Cytek Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cytek Biosciences Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Cytek Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytek Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Chularat Hospital Public Company Limited
BK:CHG
|
0.028x |
|
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
|
-0.045x |
|
Trilogy Metals Inc
TO:TMQ
|
-0.023x |
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
-0.159x |
|
Vulcan Steel Ltd
AU:VSL
|
0.138x |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
0.032x |
|
Sichuan Expressway Company Limited
F:EXF1
|
0.060x |
Annual Cash Flow Conversion Efficiency for Cytek Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cytek Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Cytek Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $341.74 Million | $-4.69 Million | -0.014x | -121.38% |
| 2024-12-31 | $395.74 Million | $25.38 Million | 0.064x | +377.33% |
| 2023-12-31 | $393.06 Million | $5.28 Million | 0.013x | +146.75% |
| 2022-12-31 | $425.55 Million | $-12.23 Million | -0.029x | -351.65% |
| 2021-12-31 | $405.38 Million | $4.63 Million | 0.011x | +101.21% |
| 2020-12-31 | $-16.03 Million | $15.16 Million | -0.946x | -386.84% |
| 2019-12-31 | $-41.70 Million | $-13.75 Million | 0.330x | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more